Subscribe
shutterstock_1686828337_arrowsmith2
arrowsmith2 / Shutterstock.com
13 October 2022Big PharmaSarah Speight

In conversation with...Beatriz San Martin, Arnold & Porter

The scientist-turned IP specialist chats to LSIPR about why she ‘loves’ the IP sector, her views on policy and funding in science and research, and the cases she’s most proud of.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
Pandemic blues: the global approach to COVID-related IP
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
Pandemic blues: the global approach to COVID-related IP
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

More on this story

Generics
CJEU ‘shuts door’ on SPCs for second medical uses
10 July 2020   The EU’s top court has ruled out extra exclusivity rewards to drug companies for products with a second medical use.
Biotechnology
Pandemic blues: the global approach to COVID-related IP
20 January 2022   While the effort to secure greater vaccine and treatment equality via an IP waiver is admirable, it could stifle innovation and create long-term problems, say Matthew Howell and Lauren Griffin of Alston & Bird.

More features

President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?